Novel 1,3,4-oxadiazole derivatives of naproxen targeting EGFR: Synthesis, molecular docking studies, and cytotoxic evaluation

被引:1
|
作者
Alsaad, Hiba N. [1 ]
AL-Jasani, Baan M. [2 ]
Mahmood, Ammar A. Razzak [3 ]
Tahtamouni, Lubna H. [4 ,5 ]
Saleh, Khaled M. [6 ]
Alsakhen, Mai F. [4 ]
Kanaan, Sana I. [4 ]
Yasin, Salem R. [4 ]
机构
[1] Univ Basrah, Coll Pharm, Dept Pharmaceut Chem, Basrah 61001, Iraq
[2] Univ Basrah, Coll Pharm, Dept Pharmacol & Toxicol, Basrah, Iraq
[3] Univ Baghdad, Coll Pharm, Dept Pharmaceut Chem, Baghdad, Iraq
[4] Hashemite Univ, Fac Sci, Dept Biol & Biotechnol, Zarqa, Jordan
[5] Colorado State Univ, Coll Nat Sci, Dept Biochem & Mol Biol, Ft Collins, CO USA
[6] Hashemite Univ, Fac Dent, Dept Basic Dent Sci, Zarqa, Jordan
关键词
ADMET; EGFR; Erlotinib; HCT-116 colorectal cancer cells; naproxen; ACID-DERIVATIVES; AGENTS; ANALOGS; DESIGN;
D O I
10.1002/ddr.22231
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The close association between inflammation and cancer inspired the synthesis of a series of 1,3,4-oxadiazole derivatives (compounds H4-A-F) of 6-methoxynaphtalene. The chemical structures of the new compounds were validated utilizing Fourier-transform infrared, proton nuclear magnetic resonance, and carbon-13 nuclear magnetic resonance spectroscopic techniques and CHN analysis. Computer-aided drug design methods were used to predict the compounds biological target, ADMET properties, toxicity, and to evaluate the molecular similarities between the design compounds and erlotinib, a standard epidermal growth factor receptor (EGFR) inhibitor. The antiproliferative effects of the new compounds were evaluated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay, cell cycle analysis, apoptosis detection by microscopy, quantitative reverse transcription-polymerase chain reaction, and immunoblotting, and EGFR enzyme inhibition assay. In silico analysis of the new oxadiazole derivatives indicated that these compounds target EGFR, and that compounds H4-A, H4-B, H4-C, and H4-E show similar molecular properties to erlotinib. Additionally, the results indicated that none of the synthesized compounds are carcinogenic, and that compounds H4-A, H4-C, and H4-F are nontoxic. Compound H4-A showed the best-fit score against EGFR pharmacophore model, however, the in vitro studies indicated that compound H4-C was the most cytotoxic. Compound H4-C caused cytotoxicity in HCT-116 colorectal cancer cells by inducing both apoptosis and necrosis. Furthermore, compounds H4-D, H4-C, and H4-B had potent inhibitory effect on EGFR tyrosine kinase that was comparable to erlotinib. The findings of this inquiry offer a basis for further investigation into the differences between the synthesized compounds and erlotinib. However, additional testing will be needed to assess all of these differences and to identify the most promising compound for further research.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Molecular Docking, Computational, and Antithrombotic Studies of Novel 1,3,4-Oxadiazole Derivatives
    Batool, Majda
    Tajammal, Affifa
    Farhat, Firdous
    Verpoort, Francis
    Khattak, Zafar A. K.
    Mehr-un-Nisa
    Shahid, Muhammad
    Ahmad, Hafiz Adnan
    Munawar, Munawar Ali
    Zia-ur-Rehman, Muhammad
    Basra, Muhammad Asim Raza
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [2] Synthesis, anticancer evaluation and molecular docking studies of 1,3,4-oxadiazole linked resveratrol derivatives
    Vema, Venakata Naresh
    Y, Bharathi Kumari
    Mandava, Venkata Basaveswara Rao
    Mussulla, Sridhar
    Addada, Ramakrishnam Raju
    A, Srinivasa Rao
    Chemical Data Collections, 2020, 30
  • [3] Naproxen Based 1,3,4-Oxadiazole Derivatives as EGFR Inhibitors: Design, Synthesis, Anticancer, and Computational Studies
    Alam, Mohammad Mahboob
    Nazreen, Syed
    Almalki, Abdulraheem S. A.
    Elhenawy, Ahmed A.
    Alsenani, Nawaf, I
    Elbehairi, Serag Eldin, I
    Malebari, Azizah M.
    Alfaifi, Mohammad Y.
    Alsharif, Meshari A.
    Alfaifi, Sulaiman Y. M.
    PHARMACEUTICALS, 2021, 14 (09)
  • [4] Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents
    Zhang, Zhi-Ming
    Zhang, Xue-Wei
    Zhao, Zong-Zheng
    Yan, Ru
    Xu, Rui
    Gong, Hai-Bin
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (10) : 3359 - 3367
  • [5] Synthesis, Molecular Docking, and Anticonvulsant Activity of 1,3,4-Oxadiazole Derivatives
    Balachandra, Anagha
    Deshpande, Shridhar Narayan
    Raj, Anjana
    Revanasiddappa, Bistuvalli C.
    JOURNAL OF HEALTH AND ALLIED SCIENCES NU, 2025, 15 (01): : 63 - 69
  • [6] Synthesis, antiinflammatory evaluation and docking analysis of some novel 1,3,4-oxadiazole derivatives
    Khatale, Pravin N.
    Bhajipale, Nitin S.
    Thangavel, Sivakumar
    Thangavelu, Prabha
    Mahajan, N. S.
    INDIAN JOURNAL OF CHEMISTRY, 2022, 61 (06): : 607 - 616
  • [7] Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents
    Yan, Ru
    Zhang, Zhi-Ming
    Fang, Xian-Ying
    Hu, Yang
    Zhu, Hai-Liang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (04) : 1373 - 1379
  • [8] Synthesis, anticholinesterase activity, molecular docking, and molecular dynamic simulation studies of 1,3,4-oxadiazole derivatives
    Durmaz, Seyma
    Evren, Asaf E.
    Saglik, Begum N.
    Yurttas, Leyla
    Tay, Naime F.
    ARCHIV DER PHARMAZIE, 2022, 355 (11)
  • [9] Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
    Ahsan, Mohamed Jawed
    Choupra, Arun
    Sharma, Rakesh Kumar
    Jadav, Surender Singh
    Padmaja, Pannala
    Hassan, Mohd. Zaheen
    Al-Tamimi, Abdulmalik Bin Saleh
    Geesi, Mohammed H.
    Bakht, Mohammed Afroz
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (01) : 121 - 138
  • [10] Synthesis and evaluation of antimicrobial activity of novel 1,3,4-oxadiazole derivatives
    Mohite, P. B.
    Bhaskar, V. H.
    ORBITAL-THE ELECTRONIC JOURNAL OF CHEMISTRY, 2011, 3 (02): : 117 - 124